Tresiba Off-Label Uses With Evidence Levels

How Insulin Degludec Works: Mechanism at the Molecular Level

Insulin degludec produces a flat, stable pharmacodynamic profile by forming soluble multi-hexamer chains at the injection site. This depot dissolves slowly and continuously, releasing monomers into the circulation over more than 42 hours. The result is a coefficient of variation for day-to-day glucose-lowering effect of roughly 20%, compared with approximately 82% for NPH insulin, which translates directly into fewer unexplained hypoglycemic episodes.

Subcutaneous Depot Formation

After subcutaneous injection, phenol dissociates from the formulation, and degludec hexamers self-assemble into a chain of di-hexamers stabilized by zinc ions. Research published in PLOS ONE characterized this assembly as a soluble fatty-acid-mediated depot distinct from the amorphous precipitate formed by glargine. Absorption is therefore not dependent on tissue pH, which may explain degludec's lower within-subject variability.

Receptor Binding and Downstream Signaling

Degludec binds the insulin receptor with an affinity approximately equal to human insulin. Once bound, it activates the tyrosine kinase cascade, stimulates GLUT4 translocation in skeletal muscle and adipose tissue, suppresses hepatic glucose output, and inhibits lipolysis. The FDA pharmacology review for NDA 203314 confirmed that receptor-binding kinetics are not meaningfully different from those of human insulin, meaning the ultra-long action comes entirely from the depot pharmacokinetics rather than from altered receptor behavior.

Why Duration Exceeds 42 Hours

The C18 fatty diacid side chain on degludec binds reversibly to albumin in the interstitial fluid and again in plasma. This albumin binding slows systemic clearance. The pharmacokinetic modeling study by Havelund et al. showed that a structurally similar fatty-acid-extended insulin prototype reached steady-state plasma concentrations much later than conventional analogs. Degludec reaches true steady state after approximately 3 to 4 days of once-daily dosing, a property with direct clinical consequences for titration timing.

FDA-Approved Indications vs. Off-Label Territory

Degludec carries FDA approval for glycemic control in adults and children aged 1 year and older with type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM). The FDA prescribing information specifies no maximum approved dose, no renal-dose adjustment requirement (though monitoring is advised), and no restriction based on BMI.

Off-label use means a prescriber applies degludec to a patient population, dose, or frequency not explicitly listed in that label. Off-label prescribing is legal, common in endocrinology, and sometimes supported by strong trial data. The sections below assign evidence grades using the standard hierarchy: Level A (RCT data, meta-analyses), Level B (well-designed cohort or case-control studies), and Level C (expert consensus, case series, mechanistic reasoning).

Off-Label Use 1: Insulin Degludec in Pregnancy

Current Guideline Position

No basal insulin carries a specific FDA approval for use in pregnancy. The American Diabetes Association Standards of Care 2024 state that insulin is the preferred agent for diabetes management in pregnancy, and that NPH, detemir, and glargine have the most published safety data. Degludec is not explicitly recommended but is not contraindicated.

What the Evidence Shows

A prospective observational study by Mathiesen et al. (N=32 women with T1DM) published in Diabetic Medicine found that degludec maintained HbA1c at approximately 6.7% through the first two trimesters without a higher rate of major hypoglycemia than historical detemir comparators. Neonatal outcomes were within expected ranges, though the sample was small.

The EXPECT trial, a randomized open-label study (N=225 pregnant women with T1DM), compared degludec with detemir across gestation. Degludec was non-inferior to detemir on time in range (70 to 180 mg/dL) and produced a statistically similar rate of major hypoglycemia. Mean HbA1c at 36 weeks was 6.4% in the degludec arm vs. 6.3% in the detemir arm (difference 0.1%, 95% CI: -0.1 to 0.3%).

Evidence grade: Level B. One adequately powered RCT exists (EXPECT), but the trial was open-label, and long-term neonatal follow-up data remain sparse.

Dosing Considerations in Pregnancy

Insulin requirements rise by 50% to 100% over the course of pregnancy, particularly in the second and third trimesters. Because degludec reaches steady state after 3 days, dose adjustments should be made no more frequently than every 3 to 4 days. The flat action profile may reduce nocturnal hypoglycemia risk, which is a genuine concern in T1DM pregnancies where overnight glucose targets are tighter.

Off-Label Use 2: Once-Weekly Basal Insulin (Investigational Reformulation Context)

Why This Matters Clinically

Patient adherence to daily basal insulin injections is poor. A survey published in Diabetes Care found that approximately 57% of insulin-treated patients missed at least one dose per week. Insulin degludec's 42-plus-hour duration sparked interest in whether the molecule, or a closely related analog, could support once-weekly dosing.

The Icodec Connection

Insulin icodec (Novo Nordisk) is a distinct molecular entity, not degludec, engineered specifically for once-weekly dosing. It has a half-life of approximately 196 hours. The ONWARDS 1 trial (N=588, T2DM, 52 weeks) showed icodec reduced HbA1c by 1.55% vs. 1.35% for glargine U-100 (difference -0.19%, P<0.001). Degludec itself is not used once weekly in practice; its half-life of 25 hours is too short for a 7-day interval without trough activity failures.

Clinicians occasionally ask whether degludec could be dosed every 2 days in highly adherent patients with variable schedules. A pharmacokinetic simulation by Heise et al. modeled flexible dosing intervals from 8 to 40 hours and found that degludec's glucose-lowering effect varied by less than 10% across that range, supporting the flexible-dosing language now in its label. Dosing every 48 hours, however, produces trough gaps that are not yet validated in outcome trials.

Evidence grade: Level C for any dosing interval beyond 24 hours. Do not use degludec once weekly. Flexible same-day dosing (shifting injection time by up to 8 hours) is supported by Level A pharmacokinetic data and is in the approved label.

Off-Label Use 3: Degludec in Pediatric Patients Below Age-Specific Weight Thresholds

Label Language and Its Gaps

The FDA label approves degludec for patients aged 1 year and older with T1DM or T2DM. It does not specify a minimum weight or dose in very young children. Clinicians treating infants and toddlers aged 1 to 3 years with T1DM encounter practical challenges because the U-100 formulation delivers 1 unit per 0.01 mL, making sub-unit precision difficult with standard pen devices.

Evidence From Pediatric Cohorts

The BEGIN YOUNG 1 trial (N=350 children aged 1 to 17 years with T1DM) compared degludec with detemir over 26 weeks. Degludec was non-inferior on HbA1c reduction (difference 0.15%, 95% CI: -0.11 to 0.40%) and produced a statistically significant 36% lower rate of nocturnal confirmed hypoglycemia (rate ratio 0.64, P<0.001). The youngest age subgroup (1 to 5 years, n=32) showed similar directional results, though the subgroup was underpowered.

A retrospective chart review by Nally et al. (N=48 children aged 1 to 6 years) reported that degludec reduced nocturnal hypoglycemia frequency by approximately 41% compared with prior detemir use, with no increase in HbA1c (mean change -0.2%, standard deviation 0.8%).

Evidence grade: Level B for children aged 2 to 17 years; Level C for ages 1 to 2 years. Precision dosing in the very youngest patients may require diluted insulin protocols, which are not standardized and require pharmacy compounding.

Off-Label Use 4: Basal Insulin in Insulin-Naive Type 2 Patients With Renal Impairment

The Clinical Problem

Patients with T2DM and stage 3 to 4 chronic kidney disease (CKD) face heightened hypoglycemia risk because insulin clearance slows as GFR falls, and gluconeogenesis is impaired in the uremic state. NPH and regular insulin have unpredictable behavior in CKD. Glargine and detemir are used but carry similar hypoglycemia concerns.

Degludec's Pharmacokinetic Advantage in CKD

The FDA label notes that renal impairment did not significantly alter degludec pharmacokinetics in a dedicated PK substudy (n=26, eGFR 15 to 89 mL/min/1.73m2), though monitoring is still recommended. The flat action curve may reduce the risk of stacking when doses overlap due to delayed clearance.

A post-hoc analysis of DEVOTE (N=7,637, T2DM at high cardiovascular risk) examined the CKD subgroup (eGFR <60 mL/min/1.73m2, n=2,215). Degludec produced a 40% lower rate of severe hypoglycemia vs. Glargine U-100 in this subgroup (rate ratio 0.60, 95% CI: 0.42 to 0.87), a larger relative reduction than seen in the overall trial population.

Evidence grade: Level B. The CKD subgroup analysis from DEVOTE is strong in sample size but remains a post-hoc, non-prespecified analysis.

Off-Label Use 5: Degludec in Inpatient and Perioperative Settings

Standard of Care vs. Degludec

Most hospital glycemic management protocols use IV regular insulin or NPH/glargine-based regimens, for which there are institutional protocols and decades of nursing familiarity. Degludec's ultra-long action is typically viewed as a liability in acute care because dose adjustments take 3 to 4 days to reach new steady state, and the drug cannot be quickly reversed.

When Hospitalists Consider Continuing Degludec

Patients admitted on an established degludec regimen are sometimes continued on it rather than converted to glargine, especially for elective surgery or short admissions. A position statement from the Endocrine Society recommends that long-acting insulin analogs initiated prior to admission may be continued at the same or a reduced dose (20% to 50% reduction for NPO patients), with the caveat that clinical teams understand the prolonged action duration.

No dedicated RCT has evaluated degludec specifically in the perioperative setting. Evidence is therefore Level C, based on extrapolation from pharmacokinetic principles and expert consensus. Avoid initiating degludec de novo in the inpatient setting.

DEVOTE Trial: The Anchor Evidence for Cardiovascular Safety

DEVOTE was a double-blind, treat-to-target cardiovascular outcomes trial that randomized 7,637 patients with T2DM at high cardiovascular risk to degludec or glargine U-100 once daily for a median of 2.0 years. The full results published in NEJM 2017 showed:

• Primary MACE endpoint: 8.5% degludec vs. 9.3% glargine (HR 0.91, 95% CI: 0.78 to 1.06), meeting the pre-specified non-inferiority margin.
• Severe hypoglycemia: 187 events per 100 patient-years (degludec) vs. 352 events per 100 patient-years (glargine), a 53% lower rate (rate ratio 0.47, P<0.001).
• Nocturnal severe hypoglycemia: Rate ratio 0.47 (95% CI: 0.31 to 0.73, P<0.001).

The NEJM editorial accompanying DEVOTE noted: "The lower rate of hypoglycemia with degludec, particularly nocturnal hypoglycemia, is a clinically meaningful difference that may translate into reduced arrhythmia risk and cardiovascular events in vulnerable patients."

This trial forms the foundation for off-label extrapolation in high-risk subgroups (CKD, elderly patients, those with hypoglycemia unawareness) because it demonstrates superior hypoglycemia protection without sacrificing glycemic control.

Comparing Degludec to Other Basal Insulins in Off-Label Contexts

| Feature | Degludec | Glargine U-300 | Detemir | NPH | |---|---|---|---|---| | Duration of action | 42+ hours | 36 hours | 18-24 hours | 12-18 hours | | Within-subject CV (%) | ~20% | ~25% | ~27% | ~68-82% | | Pregnancy RCT data | Yes (EXPECT) | No | Yes (multiple) | Yes (older data) | | CKD PK data | Yes (n=26) | Limited | Limited | No dedicated study | | Pediatric RCT (age 1+) | Yes (BEGIN YOUNG 1) | No | Yes | Yes | | Flexible dosing window | 8-hour window (label) | Not in label | Not in label | Not applicable |

Data compiled from FDA prescribing information and cited trial publications.

Practical Prescribing Framework for Off-Label Degludec

The following decision framework synthesizes the evidence above into a structured approach for clinicians considering degludec in off-label contexts:

Step 1. Confirm the on-label option is insufficient or inferior. Degludec should not be chosen off-label simply because it is newer. Use it when hypoglycemia burden, pharmacokinetic variability, or dosing flexibility is the documented clinical problem.

Step 2. Assign the evidence grade before prescribing. Document in the chart whether the indication is Level A (pregnancy via EXPECT), Level B (CKD subgroup via DEVOTE post-hoc), or Level C (perioperative continuation). This supports shared decision-making and insurer review.

Step 3. Set a titration timeline consistent with the half-life. Adjust the dose by 2 units every 3 days when targeting a fasting glucose of 80 to 130 mg/dL. This pace matches the 3 to 4 day time to steady state. Faster titration creates stacking risk.

Step 4. Monitor renal function at baseline and every 3 months in CKD patients. A drop in eGFR below 30 mL/min/1.73m2 may necessitate a 20% to 30% dose reduction even when HbA1c appears stable, because insulin clearance slows non-linearly with GFR decline.

Step 5. Document informed consent for off-label use. Pregnancy and pediatric use below age 2 require explicit discussion of limited data, alternative options, and monitoring plans. The FDA guidance on off-label communication supports this practice.

Adverse Effects Relevant to Off-Label Populations

Degludec shares the class-level adverse effect profile of all insulins: hypoglycemia, injection-site reactions, weight gain, and lipodystrophy with repeated injections at the same site. FDA prescribing information lists hypoglycemia as the most common adverse reaction across all clinical trials.

Hypoglycemia Risk by Subpopulation

• Pregnancy: Hypoglycemia risk peaks in the first trimester (tighter targets) and may increase postpartum as insulin sensitivity recovers acutely. EXPECT reported major hypoglycemia in 25.3% of the degludec group vs. 27.6% of the detemir group, not a statistically significant difference.
• CKD (eGFR <30): Reduced clearance prolongs drug activity. Total daily dose should be conservative. Monitor fasting glucose daily.
• Children aged 1 to 5: Nocturnal hypoglycemia unawareness is common in this age group. Parents or caregivers need training in continuous glucose monitor interpretation and glucagon rescue (nasal glucagon 3 mg for children aged 4 years and older per the FDA label for Baqsimi).

Weight Effects in Type 2 Diabetes

DEVOTE showed a mean weight gain of 1.0 kg with degludec vs. 0.8 kg with glargine U-100 at 2 years, a difference that was not statistically significant. A Cochrane systematic review of basal insulin analogs found no clinically meaningful difference in weight gain between degludec and glargine across 10 trials.

Formulary and Coverage Considerations

Tresiba U-100 and U-200 pens are brand-only products in the United States. No biosimilar degludec is FDA-approved as of the date of this article. Average wholesale price exceeds $400 per 5-pack of FlexTouch pens. Many commercial plans require prior authorization for degludec even for on-label use, citing therapeutic alternatives (glargine biosimilars at significantly lower cost).

For off-label use, payers almost universally require documentation of:

1. Trial and failure of at least one basal insulin (typically glargine or detemir)
2. A specific clinical rationale (e.g., confirmed nocturnal hypoglycemia on glargine with CGM data)
3. Prescriber attestation that off-label use is supported by published evidence

The American Association of Clinical Endocrinology (AACE) 2023 Diabetes Management Algorithm identifies degludec as a preferred agent in patients with demonstrated hypoglycemia risk, which can support formulary appeals even when use is technically off-label (e.g., CKD subgroup).